Dr. med Martin Spahn

Dr. Prof. med. Martin Spahn


Facharzt FMH für Urologie, h-care Partnerarzt


Spezialist für minimalinvasive, konventionelle und laparoskopische, roboterunterstützte Chirurgie (Da Vinci-Robotertechnologie) und rekonstruktive Urologie

Zentrum für Urologie Zürich
Doktorenzentrum Mutschellen

 

Wir sehen die Zukunft einer modernen, patientenorientierten und effektiven Medizin in der Zusammenarbeit mit Grundversorgern und anderen Fachspezialisten, eine enge Bindung zwischen Spital und Praxis zu gewährleisten. Die Wege bleiben kurz, Informationen gehen nicht verloren und der Patient wird aus einer Hand betreut. So ist eine logische Schlussfolgerung, dass wir auch weitere Praxisstandorte in Muri und Schaffhausen betreuen, um so die Medizin hochspezialisiert zum Patienten zu bringen.

Werdegang
2017 Ernennung zum Ausserplanmässigen Professor für Urologie der Universität Essen
2017 Ernennung zum Assoziierten Professor für Urologie Universität Bern
2012 Leitender Arzt Urologische Klinik, Inselspital Bern (Direktor Prof. Dr. med. G. Thalmann). Erweiterung der Kompetenz in der Studer-Ersatzblase. Schwerpunktmässige Ausweitung der Da Vinci radikale Prostatatektomie. Einführung der organerhaltenden Da Vinci Nieren- und Nebennierenchirurgie und der Harnröhrenrekonstruktion mit Mundschleimhaut. Aufbau des Prostatakrebszentrums und des Zentrums für Uroonkologie des University Cancer Center Bern.
2010 Gründung und Aufbau des Urogenitalen Tumorzentrum des von der Deutschen Krebsgesellschaft als Onkologisches Spitzenzentrum geförderten Comprehensive Cancer Center Mainfranken der Universität Würzburg (Direktor Prof. R. Bargou).
2007 Stellvertretender Klinikdirektor Urologische Universitätsklinik Würzburg (Direktor Prof. Dr. med. H. Riedmiller). Schwerpunkt der Tätigkeit an der europaweit führenden Klinik ist die Tumorbehandlung und Rekonstruktion des Harntraktes mit Bildung neuer Harnblasen und kontinenter Harnableitungen sowie der Versorgung nicht zufriedenstellend voroperierter Patienten aus ganz Europa. Hierbei wurden neben der laparoskopischen Chirurgie die Radikale Prostatektomie bei High-risk Prostatakarzinomen etabliert und neue komplexe Operationsverfahren zur Wiederherstellung der Harnröhre und der Harnblase entwickelt (buccal mucosa graft in the reconstruction of urethrorectal fistula, Bladder neck closure and continent vesicostomy). Aufnahme in das Nierentranslpantationsteam.
2002 Oberarzt, Leitender Oberarzt und Stellvertretender Klinikdirektor, Urologischen Klinik des Städtischen Klinikum Karlsruhe (Direktor Prof. Dr. med. D. Frohneberg). Schwerpunktausbildung in der Prostatakrebs-, Blasenkrebs- und Nierenkrebschirurgie in einer der grössten Urologischen Kliniken Europas. Einführung und Etablierung der laparoskopischen Nieren- und Nebennierenresektion. Erhalt des Schwerpunkts operative Urologie.
Ausbildung
1986 Abitur, Goethe Gymnasium Kassel
1993 Humanmedizin, Staatsexamen, Universität Hamburg
1996 Doktor der Medizin (Neue, mit Wachstumsfaktoren assoziierte Gensequenzen in Ratten Fibrosarkomzellen (Prof. Dr. F. Hölzel)), Universität Hamburg
2001 Facharzt für Urologie
2007 Schwerpunkt Spezielle Urologische Chirurgie
2011 - 2012 Privatdozent für Urologie (Klinische und molekulare Charakterisierung des Hoch-Risiko Prostatakarzinoms), Universität Würzburg und Universität Bern
2014 Nachdiplomkurs “Management im Spital”, Universität Bern
2016 Assoziierte Professur, Universität Bern
2017 - bis heute Ausserplanmässige Professur für Urologie, Universität Essen, Deutschland
Publikationen

Publikationen hier zum Download 

 

 

I           ORIGINAL ARTICLES

 

Number:                  55 (11 First-/ 5 Last Author)

Cumulative IF:        308.6

Citations:              1040

H-Index:                  18

 

 

Nr.         Autoren / Titel / Zeitschrift / Band / Seitenzahlen / Jahr                     *IF     *Zitate

 

1*

Gössi F, Spahn M, Samaras P, Beyer J, Schardt J, Pabst T Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients. Bone Marrow Transplant. 2018 Jan 24. doi: 10.1038/s41409-018-0089-5.

3.874

0

2*

Astrologo L, Zoni E, Karkampouna S, Gray PC, Klima I, Grosjean J, Goumans MJ, Hawinkels LJAC, van der Pluijm G, Spahn M, Thalmann GN, Ten Dijke P, Kruithof-de Julio M.ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models. Front Cell Dev Biol. 2017 Dec 5;5:104.

n.a.

0

3*

Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urol Oncol. 2018 Feb;36(2):79.e11-79.e17. 

3.767

 

4*

Lacombe DCoens Cde Balincourt CLicitra Lden Dulk MMachiels JPWeber DSpahn MSalgado RKasper BHau PBetsou FKataoka KCaballero CLiu YHurkmans CEvrard S. Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2017 Sep 28;86:91-100. doi: 10.1016

6.029

0

5*

Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 May 9. In press

3.723

0

6*

Spahn M, Morlacco A, Boxler S, Joniau S, Briganti A, Montorsi F, Gontero P, Kneitz B, Bader P, Frohneberg D, van Poppel H, Karnes RJ, on behalf of the “European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPAcT). Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: A multi-institutional study of 62 patients. BJU Int in press

4.338

0

7*

Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ, Everaerts W, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Graefen M, Gratzke C, Kneitz B, Marchioro G, Salas RS, Tombal B, Van Der Poel H, Walz JC, De Meerleer G, Bossi A, Haustermans K, Montorsi F, Van Poppel H, Spahn M, Briganti A, Joniau S.Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection.

Front Surg. 2016 Dec 16;3:65. doi: 10.3389/fsurg.2016.00065.

n.a.

1

8*

Gössi F, Spahn M, Zweifel M, Panagiotis S, Mischo A, Stenner F, Hess U, Berthold D, Bargetzi M, Schardt J, Pabst T. Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.285.

3.874

 

0

9*

Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium., Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. J Surg Oncol. 2016 Nov;114(6):764-768.

2.993

2

10*

Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, Serretta V, Larré S, di Stasi S, Colombo R, Babjuk M, Malmström PU, Malats N, Irani J, Baniel J, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Pisano F, Gontero P, Sylvester R. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol. 2016 Nov;34(11):484.e19-484.e25.

3.767

0

11*

Sivaraman A, Ordaz Jurado G, Cathelineau X, Barret E, Dell'Oglio P, Joniau S, Bianchi M, Briganti A, Spahn M, Bastian P, Chun J, Chlosta P, Gontero P, Graefen M, Jeffrey Karnes R, Marchioro G, Tombal B, Tosco L, van der Poel HH, Sanchez-Salas R. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. World J Urol. 2016 Feb 20.

2.743

0

12*

Dell?Oglio P, Karnes RJ, Joniau S, Spahn M, Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, Bianchi M, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. Urol Oncol. 2015 Dec 16. pii: S1078-1439(15)00570-0. doi: 10.1016/j.urolonc.2015.11.018.

3.767

0

13*

Nguyen, H. G., D. Tilki, M. A. Dall'Era, B. Durbin-Johnson, J. A. Carballido, T. Chandrasekar, T. Chromecki, G. Ciancio, S. Daneshmand, P. Gontero, J. Gonzalez, A. Haferkamp, M. Hohenfellner, W. C. Huang, E. Linares Espinos, P. Mandel, J. I. Martinez-Salamanca, V. A. Master, J. M. McKiernan, F. Montorsi, G. Novara, S. Pahernik, J. Palou, R. S. Pruthi, O. Rodriguez-Faba, P. Russo, D. S. Scherr, S. F. Shariat, M. Spahn, C. Terrone, D. Vergho, E. M. Wallen, E. Xylinas, R. Zigeuner, J. A. Libertino and C. P. Evansk (2015). "Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis."  J Urol. 2015 Aug;194(2):304-8

5.157

5

14*

Litovkin, K., A. Van Eynde, S. Joniau, E. Lerut, A. Laenen, T. Gevaert, O. Gevaert, M. Spahn, B. Kneitz, P. Gramme, T. Helleputte, S. Isebaert, K. Haustermans and M. Bollen (2015). "DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer."  PLoS One. 2015 Jun 18;10(6):e0130651.

2.806

8

15*

Briganti, A., R. J. Karnes, G. Gandaglia, M. Spahn, P. Gontero, L. Tosco, B. Kneitz, F. K. H. Chun, E. Zaffuto, M. Sun, M. Graefen, G. Marchioro, D. Frohneberg, S. Giona, P. I. Karakiewicz, H. Van Poppel, F. Montorsi, S. Joniau, C. European Multicenter Prostate Cancer, R. Translational and Group (2015). "Natural history of surgically treated high-risk prostate cancer."  Urol Oncol. 2015 Apr;33(4):163.e7-13

3.767

1

16*

Moltzahn, F., J. Karnes, P. Gontero, B. Kneitz, B. Tombal, P. Bader, A. Briganti, F. Montorsi, H. Van Poppel, S. Joniau and M. Spahn (2015). "Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients."  Prostate Cancer Prostatic Dis. 2015 Mar;18(1):31-7.

3.723

6

17*

Tilki, D., B. Hu, H. G. Nguyen, M. A. Dall'Era, R. Bertini, J. A. Carballido, T. Chandrasekar, T. Chromecki, G. Ciancio, S. Daneshmand, P. Gontero, J. Gonzalez, A. Haferkamp, M. Hohenfellner, W. C. Huang, T. M. Koppie, E. Linares, C. A. Lorentz, P. Mandel, J. I. Martinez-Salamanca, V. A. Master, R. Matloob, J. M. McKiernan, C. M. Mlynarczyk, F. Montorsi, G. Novara, S. Pahernik, J. Palou, R. S. Pruthi, K. Ramaswamy, O. Rodriguez Faba, P. Russo, S. F. Shariat, M. Spahn, C. Terrone, W. Thieu, D. Vergho, E. M. Wallen, E. Xylinas, R. Zigeuner, J. A. Libertino and C. P. Evans (2015). "Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy."  J Urol. 2015 Feb;193(2):436-42.

5.157

7

18*

*Joniau, S., *M. Spahn, A. Briganti, G. Gandaglia, B. Tombal, L. Tosco, G. Marchioro, C.-Y. Hsu, J. Walz, B. Kneitz, P. Bader, D. Frohneberg, A. Tizzani, M. Graefen, P. van Cangh, R. J. Karnes, F. Montorsi, H. van Poppel, P. Gontero and C. European Multicenter Prostate (2015). "Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer." Eur Urol. 2015 Feb;67(2):319-25.*joint first author

16.265

5

19*

Gontero, P., R. Sylvester, F. Pisano, S. Joniau, K. V. Eeckt, V. Serretta, S. Larre, S. Di Stasi, B. Van Rhijn, A. J. Witjes, A. J. Grotenhuis, L. A. Kiemeney, R. Colombo, A. Briganti, M. Babjuk, P.-U. Malmstrom, M. Oderda, J. Irani, N. Malats, J. Baniel, R. Mano, T. Cai, E. K. Cha, P. Ardelt, J. Varkarakis, R. Bartoletti, M. Spahn, R. Johansson, B. Frea, V. Soukup, E. Xylinas, G. Dalbagni, R. J. Karnes, S. F. Shariat and J. Palou (2015). "Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients."  Eur Urol. 2015 Jan;67(1):74-82.

16.265

28

20*

Joniau, S., A. Briganti, P. Gontero, G. Gandaglia, L. Tosco, S. Fieuws, B. Tombal, G. Marchioro, J. Walz, B. Kneitz, P. Bader, D. Frohneberg, A. Tizzani, M. Graefen, P. van Cangh, R. J. Karnes, F. Montorsi, H. Van Poppel and M. Spahn. European Multictr Prostate Canc (2015). "Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study."  Eur Urol. 2015 Jan;67(1):157-64

16.265

50

21*

Litovkin K, Joniau S, Lerut E, Laenen A, Gevaert O, Spahn M, Kneitz B, Isebaert S, Haustermans K, Beullens M, Van Eynde A, Bollen M. Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol. Nov. 2014, Vol. 140, 1849-61.

3.503

11

22*

Vergho D, Kneitz S, Kalogirou C, Burger M, Krebs M, Rosenwald A, Spahn M, Löser A, Kocot A, Riedmiller H, Kneitz B. Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava. PLoS One,  2014 Oct 3;9(10):e109877. doi:10.1371/journal.pone.0109877. eCollection 2014

2.806

12

23*

Tilki D, Nguyen HG, Dall'era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus.  Eur Urol. 2014 Sep;66(3):577-83

16.265

25

24*

Hailer, A., T. G. P. Grunewald, M. Orth, C. Reiss, B. Kneitz, M. Spahn and E. Butt (2014). "Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration."  Oncotarget. 2014 Jun 30;5(12):4144-4153

5.168

29

25*

Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Ströbel P, Gessler M, Riedmiller H, Spahn M. Survival in high-risk prostate cancer patients is predicted by mir-221, which regulates proliferation, apoptosis and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res. 2014 May 1;74(9):2591-603.

9.122

42

26*

Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, Riedmiller H, Kneitz B. Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma. BMC Cancer. 2014 Jan 15;14:25.

3.288

17

27*

Kalogirou C, Spahn M, Krebs M, Joniau S, Lerut E, Burger M, Scholz CJ, Kneitz S, Riedmiller H, Kneitz B. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.

Int J Mol Sci. 2013 Oct 29;14(11):21414-34.

3.226

18

28*

Loeser, A., M. Neumann, A. Kocot, D. C. Vergho, M. Spahn and H. Riedmiller (2013). "Serum carcino-embryonic antigen (CEA) and its possible use as tumor marker for secondary tumors in urinary intestinal reservoirs."  Urol Oncol. 2013 Jul;31(5):644-8.

3.767

3

29*

Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, Riedmiller H, Kneitz B. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One. 2013 Jun 14;8(6):e65064

2.806

36

30*

Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R; on behalf of the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis. Eur Urol. 2013 Apr;63(4):693-701

16.265

52

31*

Belharazem D, Kirchner M, Geissler F, Bugert P, Spahn M, Kneitz B, Riedmiller H, Sauer C, Küffer S, Trojan L, Bolenz C, Michel MS, Marx A, Ströbel P. Relaxed imprinting of IGF2 in peripheral blood cells of patients with a history of prostate cancer. Endocr Connect. 2012 Oct 24;1(2):87-94

n.a.

4

32*

Spahn M, Briganti A, Capitanio U, Kneitz B, Gontero P, Karnes JR, Schubert M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.

J Urol. 2012 Jul;188(1):84-90.

5.157

12

33*

Joniau S, Hsu CY, Gontero P, Spahn M, Van Poppel H. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. Scand J Urol Nephrol. 2012 Jun;46(3):164-71.

1.243

16

34*

Kälble T, Hofmann I, Thüroff JW, Stein R, Hautmann R, Riedmiller H, Vergho D, Hertle L, Wülfing C, Truß M, Roth S, von Rundstedt FC, Albers P, Gschwend J, Herkommer K, Humke U, Spahn M, Bader P, Steffens J, Harzmann R, Stief CG, Karl A, Müller SC, Waldner M, Noldus J, Kleinschmidt K, Alken P, Kopper B, Fisch M, Lampel A, Stenzel A, Fichtner J, Flath B, Rübben H, Juenemann KP, Hautmann S, Knipper A, Leusmann D, Strohmaier W, Thon WF, Miller S, Weingärtner K, Schilling A, Piechota H, Becht JE, Schwaibold H, Bub P, Conrad S, Wenderoth U, Merkle W, Rösch W, Otto T, Ulshöfer B, Westenfelder M. Secondary malignancies in urinary diversions. Urologe A. 2012 Apr;51(4):500, 502-6

0.289

2

35

Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol. 2012 Mar;61(3):584-92

16.265

62

36

Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schröder F, van Cangh P, van Poppel H, Spahn M. The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Adv Urol. 2012;2012:612707.

n.a.

0

37

Vergho, D. C., A. Loeser, A. Kocot, M. Spahn and H. Riedmiller (2012). "Tumor thrombus of inferior vena cava in patients with renal cell carcinoma - clinical and oncological outcome of 50 patients after surgery." BMC research notes 5: 5-5

n.a.

5

38

Gontero P, Spahn M, Tombal B, Bader P, Hsu CY, Marchioro G, Frea B, Van Der Eeckt K, Kneitz B, Frohneberg D, Tizzani A, Van Poppel H, Joniau S. Is there a prostate-specific antigen upper limit for radical prostatectomy? BJU Int. 2011 Oct;108(7):1093-100.

4.338

14

39

Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H, Haaf M, Kroiss M, Jurowich C, Langer P, Oelkers W, Spahn M, Willenberg HS, Mäder U, Allolio B, Fassnacht M. Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int. 2010 Dec;107(50):885-91

4.257

28

40

Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B; German ACC Registry Group. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010 Nov;95(11):4925-32.

5.531

64

41

Kocot A, Spahn M, Loeser A, Lopau K, Gerharz EW, Riedmiller H. Long-term results of a staged approach: continent urinary diversion in preparation for renal transplantation. J Urol. 2010 Nov;184(5):2038-42.

5.157

5

42

Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M; German Adrenocortical Carcinoma Registry Group. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010 Oct;58(4):609-15.

16.265

123

43

Reiss C, Haneke T, Völker HU, Spahn M, Rosenwald A, Edelmann W, Kneitz B. Conditional inactivation of MLH1 in thymic and naive T-cells in mice leads to a limited incidence of lymphoblastic T-cell lymphomas. Leuk Lymphoma. 2010 Oct;51(10):1875-86.

2.755

8

44

Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H, Kneitz B. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 2010 Jul 15;127(2):394-403.

5.513

117

45

Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, Tombal B, Kneitz B, Hsu CY, Van Der Eeckt K, Bader P, Frohneberg D, Tizzani A, Van Poppel H. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol. 2010 Jul;58(1):1-7; discussion 10-1

16.265

87

46

Spahn M, Kocot A, Loeser A, Kneitz B, Riedmiller H.

Last resort in devastated bladder outlet: bladder neck closure and continent vesicostomy--long-term results and comparison of different techniques. Urology. 2010 May;75(5):1185-92.

2.309

11

47

Spahn M, Weiss C, Bader P, Frohneberg D, Studer UE, Burkhard FC. The role of exenterative surgery and urinary diversion in persistent or locally recurrent gynecological malignancy: complications and survival. Urol Int. 2010;85(1):16-22.

1.611

6

48

Spahn M, Weiss C, Bader P, Ströbel P, Gerharz EW, Kneitz B, Frohneberg D. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation. Urol Int. 2010;84(2):164-73.

1.611

24

49

Loeser A, Vergho DC, Katzenberger T, Brix D, Kocot A, Spahn M, Gerharz EW, Riedmiller H. Testis-sparing surgery versus radical orchiectomy in patients with Leydig cell tumors. Urology. 2009 Aug;74(2):370-2

2.309

18

50

Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol. 2009 Jun;55(6):1293-9.

16.265

55

51

Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M. Complete resection of urothelial cancer metastases with curative intent. Urologe A. 2009 Feb;48(2):143-50.

0.289

2

52

Spahn M, Vergho D, Riedmiller H. Iatrogenic recto-urethral fistula: perineal repair and buccal mucosa interposition. BJU Int. 2009 Jan;103(2):242-6.

4.338

13

53

Knoll T, Michel MS, Cueva-Martínez A, Spahn M, Bross S, Alken P, Köhrmann KU. Evaluation of superficial papillary ablation by endoscopic lasers in an ex vivo kidney model.

J Endourol. 2002 Apr;16(3):195-200.

2.27

3

54

Spahn M, Portillo FJ, Michel MS, Siegsmund M, Gaa J, Alken P, Jünemann KP. Color Duplex sonography vs. computed tomography: accuracy in the preoperative evaluation of renal cell carcinoma. Eur Urol. 2001 Sep;40(3):337-42.

16.265

7

55

Krautschick A, Spahn M, Christman S, Michel MS, Alken P.: Experimentell induzierte Deposition von Kalzium-Oxalat- Kristallen in der Kaninchenniere und Bedeutung für die humane Lithiasis. Aktuelle Urologie,30, 1999; 35-40

0.306

0

#   Liegt noch nicht vor

*     Impactfaktoren gemäss Journal Citation report  des Institute for Scientific Information (2016)

**    Zitationen gemäss Institute for Scientific Information (27.07.2017)

 

 

 

II          CASE REPORTS

 

Number:                    5 (1 First Author)

Cumulative IF:           4.1

Citation:                     5

 

 

Nr.         Autoren / Titel / Zeitschrift / Band / Seitenzahlen / Jahr                  *IF       **Zitate

1

Kocot A, Spahn M, Loeser A, Riedmiller H. Recto-vesico-cutaneous fistula following salvage cryotherapy of the prostate due to recurrent localized prostate cancer]. Urologe A. 2011 Nov;50(11):1428-30.

0.289

1

2

Loeser A, Kocot A, Spahn M, Riedmiller H. Urethro-crural fistula to the adductor canal. Late complication following radiotherapy for recurrent prostate cancer]. Urologe A. 2011 Nov;50(11):1438-40.

0.289

0

3

Letsch M, Spahn M, Beissert M, Topp MS, Gerharz EW, Riedmiller H. The worst case: giant exulcerating seminoma. Urol Int. 2010;84(1):113-5.

1.611

1

4

Loeser A, Katzenberger T, Spahn M, Gerharz EW, Riedmiller H. Metanephric adenoma in a two-year-old child. Urol Int. 2009;83(1):119-21.

1.611

1

5

Spahn M, Portillo FJ, Grobholz R, Jünemann KP, Alken P. Fibromyxoid pseudosarcoma of the urinary bladder. Case report and review of the literature of a rare disease]. Urologe A. 2001 Jul;40(4):315-8.

0.289

2

 

*     Impactfaktoren gemäss Journal Citation report  des Institute for Scientific Information (2016)

**    Zitationen gemäss Institute for Scientific Information (27.07.2017)

                                                                                          

 

III         REVIEW ARTICLE

 

Number:                  24 (9 First-/Last Author)

Cumulative IF:        73.5

Citation:                 139

 

Nr.         Autoren / Titel / Zeitschrift / Band / Seitenzahlen / Jahr                     *IF     *Zitate

 

1*

Multi-disciplinary quality assurance and control in oncological trials: perspectives from EORTC European Journal of Cancer, in press

De Balincourt C, Caballero C, Coens C, van den Dulk M, Hau HP, Kasper B, Salgado R, Spahn M, Weber D and Yan Liu for the EORTC QAC

6.029

0

2*

Zoni, E., Karkampouna, S., Thalmann, G. N., Kruithof-de Julio, M. and Spahn, M. Emerging aspects of microRNA interaction with TMPRSS2-ERG and endocrine therapy

Mol Cell Endocrinol. 2017 Feb 9. pii: S0303-7207(17)30089-8. doi: 10.1016/j.mce.2017.02.009.

3.754

0

3*

Moltzahn F, Dal Pra A, Furrer M, Thalmann G, Spahn M.

Urethral strictures after radiation therapy for prostate cancer. Investigative and clinical urology   Volume: 57   Issue: 5   Pages: 309-315   Published: SEP 2016

n.a.

1

4*

Moschini M, Spahn M, Mattei A, Cheville J, Karnes RJ. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Med. 2016 Apr Moschini M, BMC Med. 2016 Apr 4;14(1):67. doi: 10.1186/s12916-016-0613-7.

7.901

16

5*

Rozet F, Roumeguère T, Spahn M, Beyersdorff D, Hammerer P. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. World J Urol. 2016 Nov;34(11):1505-1513.

2.743

0

6*

Spahn M und Boxler S. Harnableitung beim älteren Patienten. Der Urologe 2015 Dec;54(12):1753-7

0.289

0

7*

Spahn M, Boxler S, Joniau S, Moschini M, Tombal B and Karnes RJ. What is the Need for Prostatic Biomarkers in Prostate Cancer Management? Curr Urol Rep. 2015 Oct;16(10):70. doi: 10.1007/s11934-015-0545-3.

2.124

3

8*

Martinez-Salamanca JI, Linares E, Gonzalez J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, Shariat SF, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Current Urology Reports, 15(5) Art. No. 404

2.124

15

9*

De Meerleer G, Khoo V, Escudier B., Joniau S, Bossi A., Ost P, Briganti A, Fontayne V, Van Vulpen M, Lumen N, Spahn M and Mareel M. Radiotherapy for renal-cell carcinoma.  Lancet Oncol. 2014 Apr;15(4):e170-7.

33.9

50

10*

Joniau S, Tosco L, Briganti A, Vanden Broeck T, Gontero P, Karnes RJ, Spahn M, Van Poppel H. Results of surgery for high-risk prostate cancer. Curr Opin Urol. 2013 Jul;23(4):342-8

1.796

13

11*

Joniau S, Van der Eeckt K, Briganti A, Gontero P, Van Bruwaene S, Jeffrey Karnes R, Spahn M, Van Poppel H. Current role of surgery for high risk prostate cancer. Arch Esp Urol. 2013 Apr;66(3):259-73, 259-74

#

2

12*

Spahn M and Haeni K. Approach to prostate cancer in men older than 75 years : Active or passive?  Urologe A. 2012 Oct;51(10):1368-74.

0.289

1

13*

Oderda M, Joniau S, Spahn M, Gontero P. Debulking surgery in the setting of very high-risk prostate cancer scenarios. BJU Int. 2012 Sep;110(6 Pt B):E192-8.

4.338

15

14

Spahn M and Krebs M. How should hormone therapy for castration-resistant prostate cancer be continued? Urologe A. 2012 Jan;51(1):15-9.

0.289

1

15

Van Baelen A, Mottet N, Spahn M, Briganti A, Gontero P, Joniau S. Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer. Adv Urol. 2012;2012:983058.

#

0

16

Riedmiller H and Spahn M. Surgery illustrated - surgical atlas: Open staghorn stone surgery. BJU Int. 2010 Sep;106(5):730-46.

4.338

0

17

Spahn M, Kocot A, Riedmiller H. Interventional and surgical treatment of urethral strictures. End-to-end anastomosis. Urologe A. 2010 Jun;49(6):720, 722-6.

0.289

0

18

Kocot A, Spahn M, Riedmiller H. Renal transplantation and urinary diversion. Urologe A. 2009 Dec;48(12):1452-5.

0.289

1

19

Wendt-Nordahl G, Evan AP, Spahn M, Knoll T. Calcium oxalate stone formation. New pathogenetic aspects of an old disease.

Urologe A. 2008 May;47(5):538, 540-44.

0.289

4

20

Spahn M, Bader P, Westermann D, Echtle D, Frohneberg D. Bladder carcinoma during pregnancy. Urol Int. 2005;74(2):153-9.

1.611

11

21

Trompeter M, Spahn M. Postoperative radiologic evaluation in uroradiology. Part 2: Bladder, prostate, and testis. Radiologe. 2003 Aug;43(8):677-86

0.404

0

22

Trompeter M, Spahn M. Postoperative evaluation in uroradiology. Part 1: Nephrolithiasis, renal tumors and diseases ot the ureter.

Radiologe. 2003 Jul;43(7):581-93

0.404

0

23

Fernández Arancibia MI, Martínez Portillo FJ, Musial A, Spahn M, Jünemann KP, Alken P. Diagnosis and therapeutic options for prolonged erection and priapism: up-date review. Arch Esp Urol. 2000 Dec;53(10):919-27.

#

0

24

Manning M, Spahn M, Jünemann KP. Vascular surgery, implant surgery and vacuum erectile aids. Review-overview-prospects of 3 therapy options in erectile dysfunction. Urologe A. 1998 Sep;37(5):509-15.

0.289

6

#   Liegt noch nicht vor

*     Impactfaktoren gemäss Journal Citation report  des Institute for Scientific Information (2016)

**    Zitationen gemäss Institute for Scientific Information (27.07.2017)

 

 

IV        BOOK CHAPTER

 

Number:                          10

First-/Senior Author:          7

 

Nr.         Autoren / Titel / Zeitschrift / Band / Seitenzahlen / Jahr

1*

Ambühl D, Thalmann G and Spahn M. Management of non-metastatic failure following local therapy (BCR, salvage RP, salvage PLND) in “Prostate Cancer" by Springer International, in press

B

 

2*

Joniau,S, Briganti A, DeMeerleer G, Gontero P, Spahn M, Bruwaene and Karnes J. High risk prostate cancer. Oxford Textbook of Urological Surgery, Edited by F. Hamdy and E. Eardley, Oxford University press in press

B

 

3*

Spahn M.

Quality of Life with Orthotopic Bladder Substitution - Use of Validated Questionnaires –in: Keys to Successful Orthotopic Bladder Substitution.

Edited by UE Studer, Springerverlag, in press

B

 

4*

Thalmann G and Spahn M. Outcome of different forms of androgen deprivation therapy in prostate cancer. In: Advances in androgen deprivation with a GnRH antagonist in prostate cancer patients. Edited by T.M. de Reijke. Minerva Medica Verlag, in press.

B

-

5*

Thalmann G and Spahn M. Managing rising PSA, in naïve and post therapy patients. In: Prostate cancer: Diagnosis and Clinical management. Edited by Wheelan P, Tewari A and Graham J. Wiley-Blackwell Verlag, in press.

B

-

6*

Bossi A, Joniau S, Spahn M, Tombal B. How can high?risk non?metastatic disease be appropriately managed? In High?risk non?metastatic and metastatic prostate cancer. Edt.by Mottrie/Tombal/Van Poppel/De Meerleer; by Mirrors of Medicine, 2015, in press.

B

-

7

Kocot A, Spahn M, Riedmiller H: „Komplikationen bei der Harnröhrenchirurgie, allgemeine Aspekte, End-zu-End Anastomose, Mundschleimhaut“ in „Komplikationen in der Urologie.“ Anheuser/Steffens (Hrsg.), Thieme Verlag 2011

B

-

8

Spahn M, Bader P, Frohneberg D.: „Cock rings - das Dilemma nach dem Spass“ in „Kuriositäten aus dem urologischen Alltag“. C. Doehn, D. Jocham, Steinkopf Verlag 2009.

B

-

9

Frohneberg D., Spahn M.: „Renale und Retroperitoneale Raumforderungen“ in „Urologische Differenzialdiagnose“. J.W. Thüroff (Hrsg.), Thieme Verlag 2007.

B

-

10

Spahn M, Manning M, Jünemann KP.:  „Intracavernosal Therapy“ in „Textbook of erectile dysfunction“. C.C. Carson, R. Kirby and I. Goldstein (Hrsg.), Isis Medica Media 1999.

B

-

 

 

V         LETTER; EDITORIAL

 

Number:                  15 (13 First-/Last Author)

Cumulative IF:      262.5

Citatione:                14

 

Nr.         Autoren / Titel / Zeitschrift / Band / Seitenzahlen / Jahr           *IF            **Zitate

1*

Spahn M. Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Eur Urol. 2018 Jan;73(1):141-142.

16.265

0

2*

Spahn M. Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Eur Urol. 2018 Jan;73(1):141-142.

16.265

0

3*

Spahn M, Dal Pra A, Aebersold D, Tombal B. Radiation Therapy Versus Radical Prostatectomy: A Never-ending Discussion. Eur Urol. 2016 Feb 5. pii: S0302-2838(16)00168-8. doi: 10.1016/j.eururo.2016.01.049. [Epub ahead of print]

16.265

1

4*

Dal Pra A. and Spahn.M. Who is the patient who needs treatment intensification? Eur Urol 2016 Apr;69(4):e74-5

16.265

0

5*

Spahn M. More nomograms or better lymph node?dissection what do we need in prostate cancer?  BJU Int, 2015 Nov;116(5):676-7

4.338

0

6*

Gontero P, Spahn M, Marchioro G, Karnes JR, Briganti A, Frea B, Ricardi U, van Poppel H, Joniau S. Salvage radical prostatectomy in nonmetastatic castration-resistant prostate cancer patients who received previous radiotherapy: a feasibility study. Eur Urol. 2014 Jan;65(1):254-5.

16.265

0

7*

Joniau S, Tosco L, Van Poppel H, Spahn M. Minimally invasive vs open radical prostatectomy in high-risk prostate cancer: comparing apples and pears? BJU Int. 2013 Oct;112(6):711-2

4.338

1

8*

Spahn M. Is It Time To Change the Treatment Paradigm for Lymph Node-Positive Prostate Cancer? Eur Urol. 2013 Jul 2. pii: S0302-2838(13)00655-6

16.265

0

9

Spahn M and Joniau S. Positive surgical margin at radical prostatectomy: futile or surgeon-dependent predictor of prostate cancer death? Eur Urol. 2012 Sep 5. S.0302-2838(12)

16.265

4

10*

Sooriakumaran P, Spahn M, Wiklund P. Apples and oranges: comparison of treatment methods for prostate cancer using biochemical recurrence as an endpoint. BJU Int. 2012 Aug;110(4):477-8.

4.338

6

11

Joniau S, Van den Bergh L, Peeters C, Haustermans K, Spahn M. Nodal staging in prostate cancer: still an unresolved issue. Eur Urol. 2012 Jun;61(6):1139-41.

16.265

2

12

Joniau S and Spahn M. Words of wisdom. Re: Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. Eur Urol. 2011 Nov;60(5):1121-2.

16.265

1

13

Spahn M., Riedmiller H.: Re-Editorial comment to: Bladder Neck Closure and Continent Vesicostomy –Long Term Results and Comparison of Different Techniques. Urology, 2010, May; 75(5):1192.

2.309

0

14

Spahn M, Joniau S, Kneitz B, Gontero P, van Poppel H: Reply from Authors re: Defining and Treating High-risk Prostate Cancer: Can We Do Better? European Urology 2010, 58, 8-9.

16.265

0

15

Spahn M, Kneitz B, Gontero P, van Poppel H, Joniau S: Reply to Endre Zoltan Neulander and Zev Wejsman's Letter to the Editor re: Martin Spahn, Steven Joniau, Paolo Gontero, et al. Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients. Eur Urol 2010;58:1-7. Eur Urol. 2010 May 20.

16.265

0

 

*     Impactfaktoren gemäss Journal Citation report  des Institute for Scientific Information (2016)

**    Zitationen gemäss Institute for Scientific Information (27.07.2017)

 

VI        PUBLISHED ABSTRACTS

 

Number:                      173

First-/Last Author:          70

 

1*

Zoni, E., Krebs, M., Herreiner, P., Kalogiro, C., Chen, L. P., Snaar-Jagalska, E., Thalmann, G. N., Kruithof-de Julio, M., Riedmiller, H., Kneitz, B. And Spahn, M. Mir-221 modulates tumor growth in vivo and is a regulator of TGF-b Signaling in human prostate cancer. Journal of Urology. 2017;197(4):E1326-E.

 

 

2*

Lorentz, A., Tai, C., Capitanio, U., Carballido, J., Ciancio, G., Daneshmand, S., Evans, C., Gontero, P., Haferkamp, A., Hohenfellner, M., Huang, W., Espinos, E. L., Martinez-Salamanca, J., McKiernan, J., Montorsi, F., Pahernik, S., Palou, J., Pruthi, R., Russo, P., Scherr, D., Spahn, M., Terrone, C., Tilki, D., Vera-Donoso, C., Vergho, D., Wallen, E., Zigeuner, R., Libertino, J. and Master, V. External validation of the mayo clinic stage, size, grade, and necrosis score in patients with renal cell carcinoma and venous tumor thrombus. Journal of Urology. 2017;197(4):E66-E7.

 

 

3*

Karkampouna, S., Zoni, E., la Manna, F., Astrologo, L., Beimers, L., Kloen, P., Grosjean, J., Klima, I., Spahn, M., Kruithof-de Julio, M. and Thalmann, G. N. Patient derived xenografts as preclinical models of urological malignancies. Journal of Urology. 2017;197(4):E570-E.

 

 

4*

Karkampouna, S., la Manna, F., Zoni, E., Beimers, L., Kloen, P., Wetterwald, A., Grosjean, J., Klima, I., Cecchini, M. G., Spahn, M., Thalmann, G. N. and Kruithof-de Julio, M.

Modelling prostate cancer using primary and metastatic canceroids. Journal of Urology. 2017;197(4):E539-E.

 

 

5*

Bianchi, M., Colicchia, M., Gandaglia, G., Munegato, S., Fossati, N., Bandini, M., Stabile, A., Dell'Oglio, P., Suardi, N., Gontero, P., Karnes, R. J., Joniau, S., Spahn, M., Montorsi, F. and Briganti, A.. Assessing the 20-year outcomes of radical prostatectomy for high risk prostate cancer: results from a large, multi-institutional series. Journal of Urology. 2017;197(4):E986-E7.

 

 

6*

Spahn M, Golfinopoulos V, Joniau S, van Leenders A, Lacomb D, Tombal B. Challenges and opportunities for molecular driven care in prostate cancer: The EORTC spectapros program. Oncology Research and Treatment. 2016;39:163-.

 

 

7*

Spahn M, Boxler S, Metzger T, Thalmann G. Robot-assisted laparoscopic partial adrenalectomy for aldosterone-producing adenomas.. Eur Urol Suppl, in press (Video)

S

 

8*

S. Karkampouna, F. la Manna, E. Zoni, L. Beimers, P. Kloen, A. Wetterwald, J. Grosjean, I. Klima, M.G. Cecchini, M. Spahn, G.N. Thalmann, M. Kruithof-de Julio. Characterization and personalized treatment response in primary and metastatic prostate canceroids. Eur Urol Suppl, in press

S

 

9*

L. Astrologo, E. Zoni, S. Karkampouna, P.C. Gray, I. Klima, J. Grosjean, M.J. Goumans, L.J.A.C. Hawinkels, G. van der Pluijm, P. ten Dijke, M. Spahn, G.N. Thalmann, M. Kruithof de Julio. ALK1Fc suppresses tumor growth by impairing proliferation of human prostate cancer cells in vitro and in vivo. Eur Urology Suppl, in press

S

 

10*

Krebs M, Zoni E, Herreiner P, Chen L, Snaar-Jagalska E, Thalmann G, Kruithof-de Julio M, Riedmiller H, Kneitz B, Spahn M. miR-221 modulates tumor growth in vivo and is a ( might be too strong??) regulator of TGF-β signaling in human prostate cancer. Meeting oft he European Society of Urological Research, Parma, 2016

S

 

11*

D. Vazquez-Martul Pazos, V.C. Chantada, U. Capitanio, J.A. Carballido, T. Chromecki, G. Ciancio, S. Daneshmand, C.P. Evans, P. Gontero, J. González, A. Haferkamp, M. Hohenfellner, W.C. Huang, T.M. Koppie, E. Linares Espinós, A. Lorentz, J.I. Martínez-Salamanca, A.Y. Mass, V.A. Master, J.M. McKiernan, F. Montorsi, P. O'Malley, S. Pahernik, J. Palou, J.L. Pontones Moreno, R.S. Pruthi, O. Rodriguez Faba, P. Russo, D.S. Scherr, S.F. Shariat, M. Spahn, C. Terrone, D. Tilki, C.D. Vera Donoso, D. Vergho, E.M. Wallen, R. Zigeuner, J.A. Libertino, International Renal Cell Carcinoma-Venous Thrombus Consortium. Preoperative renal artery embolization in renal carcinoma with venous thrombus: Preliminary results of a multicenter study. Eur Urol Suppl 2016; 15(3);e524

S

 

12*

M. Oderda, P. Gontero, R. Sanchez-Salas, J. Walz, P. Bastian, H. Van Der Poel, F. Chun, M. Graefen, B. Tombal, G. Marchioro, P. Chlosta, L. Tosco, M. Bianchi, A. Briganti, M. Spahn, R.J. Karnes, S. Joniau, EMPaCT. Gleason score upgrading to 8–10 predicts biochemics from al recurrence in patients undergoing radical prostatectomy: Analysis on 7310 high-risk patient the EMPaCT database. Eur Urol Suppl 2015; 14/2;e936

S

 

13*

M. Bianchi, A. Briganti, J. Karnes, G. Gandaglia, N. Fossati, M. Spahn, P. Gontero, L. Tosco, B. Kneitz, F. Chun, E. Zaffuto, D. De Ridder, M. Sun, M. Graefen, G. Marchioro, D. Frohneberg, B. Guilloneau, S. Giona, R. Sanchez-Salas, X. Cathelineau, P. Karakiewicz, H. Van Poppel, F. Montorsi, S. Joniau. Historical trends in high-risk prostate cancer patients characteristics: A 27 years old observational study from the European multicenter prostate cancer clinical and translational research group (EMPaCT) data base. European Urology Supplements

Volume 15, Issue 3, March 2016, Pages e163, e163a

S

 

14*

E. Linares Espinós, J.I. Martinez-Salamanca, J. Carballido, J. Gonzalez, U. Capitanio, V. Chantada, T. Chromecki, G. Ciancio, S. Daneshmand, C.P. Evans, P. Gontero, A. Haferkamp, M. Hohenfellner, W. Huang, T.M. Koppie, A. Lorentz, V. Master, J. McKiernan, F. Montorsi, P. O'Malley, S. Pahernik, J. Palou, J.L. Pontones, R. Pruthi, O. Rodriguez Faba, P. Russo, D.S. Scherr, M. Spahn, C. Terrone, D. Tilki, D. Vázquez-Martul,, C. Vera Donoso, D. Vergho, E. Wallen, R. Zigeuner, J. Libertino. Impact of surgical volume on perioperative outcomes after nephrectomy with tumor thrombectomy. European Urology Supplements

Volume 15, Issue 3, March 2016, Pages e521, e521a

S

 

15*

Spahn M, Boxler S, Joniau S, Briganti A, Abdolah F, Gontero P, Kneitz B, Bader P, Frohneberg D, van Poppel H, Karnes JR. Ergebnisse der radikalen Zystektomie bei ct4 „very- high risk“ Prostatakarzinom: eine multizentrische out- come studie von 62 Patienten?. Der Urologe, Vol 54 (1S), September 2015

S

 

16*

Boxler S, Tombal B, Gontero P, Karnes J, Briganti A, Kneitz B, Frohneberg D, Chun F, Gräfen M, Bastian P,  Joniau, Spahn, M. Time to biochemical recurrence is a surrogate endpoint for cancer related death in patients with high risk pros- tate cancer?. Der Urologe, Vol 54 (1S), September 2015

S

 

17*

Boxler S, Gross T, Thalmann, G, Studer U, Spahn M. Rezidivmuster in lymphknoten positiven Prostatakarzi- nompatienten nach extendierter pelviner lymphaden- ektomie und radikaler Prostatektomie – der natürliche Verlauf der erkrankung. Der Urologe, Vol 54 (1S), September 2015

S

 

18*

Goessi F, Zweifel  M, Schardt J, Spahn M, Thalmann G, Pabst T. Comparison of three or fewer sequential high-dose chemotherapy cycles as salvage treatment in germ-cell tumors?. Der Urologe, Vol 54 (1S), September 2015

S

 

19*

Krebs, M, Behrmann, C, Kalogirou C, Kneitz  S, Spahn M, Riedmiller H, Kneitz B. mir-221 augments trAIl-mediated apoptosis in prostate cancer cells. Der Urologe, Vol 54 (1S), September 2015

S

 

20*

S. Boxler, T. Gross, G.N. Thalmann, U.E. Studer, M. Spahn The natural course of disease in prostate cancer patients with lymph node involvement after extended pelvic lymphadenectomy and radical prostatectomy. European Urology Supplements, Volume 14, Issue 2, April 2015, Page e457  

S

 

21*

M. Schubert, S. Kneitz, M. Spahn, H. Riedmiller, B. Kneitz Absolute quantification of miRNA-221 in high risk prostate cancer by qRT-PCR – a new and sensitive method for measurement of miRNA expression levels. European Urology Supplements, Volume 14, Issue 2, April 2015, Page e524

S

 

22*

M. Oderda, P. Gontero, R. Sanchez-Salas, J. Walz, P. Bastian, H. Van Der Poel, F. Chun, M. Graefen, B. Tombal, G. Marchioro, P. Chlosta, L. Tosco, M. Bianchi, A. Briganti, M. Spahn, R.J. Karnes, S. Joniau, EMPaCTGleason score upgrading to 8–10 predicts biochemics from al recurrence in patients undergoing radical prostatectomy: Analysis on 7310 high-risk patient the EMPaCT database. European Urology Supplements, Volume 14, Issue 2, April 2015, Pages e936-e936a

S

 

23*

G. Ordaz Jurado, R. Sánchez Salas, A. Sivaraman, S. Joniau, M. Bianchi, M. Spahn, P. Bastian, J. Chun, P. Chlosta, P. Gontero, M. Graefen, R.J. Karnes, G. Marchioro, B. Tombal, L. Tosco, H. Van Der Poel, X. Cathelineau, European Multicenter Prostate Cancer Clinical and Translational research group (EMPaCT), Lier, BelgiumCharlson score predicts overall survival and cancer related death in elderly patients featuring high risk prostate cancer

                       European Urology Supplements, Volume 14, Issue 2, April 2015, Pages e935-e935

S

 

24*

F. Pisano, J.A. Witjes, G. Dalbagni, S. Shariat, S. Joniau, V. Serretta, J. Palou, S. Di Stasi, S. Larré, R. Colombo, M. Babjuk, P.U. Malmstrom, J. Irani, N. Malats, J. Baniel, T. Cai, E. Cha, P. Ardelt, J. Varkarakis, R. Bartoletti, M. Spahn, et al.The impact of different BCG strains on outcome in a large cohort of T1G3 patients treated with BCG. European Urology Supplements, Volume 14, Issue 2, April 2015, Pages e948-e948a

S

 

25*

Bianchi M, Karnes RJ, Joniau S, Gandaglia G, Spahn M, Gontero P, Sanchez-Salas R, Kneitz B, ChunF, Karakiewicz P, Graefen M, Marchioro G, Frohneberg D, Van Poppel H, MontorsiF et al. Long-term outcomes of very high risk prostate cancer patients treated with radical prostatectomy with or without adjuvant treatments. Results of a competing risks, multi institutional analysis. The Journal of Urology , Volume 193 , Issue 4 , e1037, 2015

S

 

26*

Pak, J; Capitanio U, CarballidoJ, Chantada, V, Chromecki, T, Ciancio G, Daneshmand S, Evans C, GonteroP, González, J, Haferkamp A, Hohenfellner M, Huang W. Koppie, Espinós, E, Lorentz A, Martínez-Salamanca J, Martul D, Mass, Master V, Mir C, Montorsi F, Novara G, O'Malley P,Pahernik S, Palou J, Moreno J, Pruthi R, Faba,O,.Russo P, Shariat, S, Spahn M, Terrone C, Tilki D, Donoso C, Vergho D; WallenE, Zigeuner R, Libertino J. The significance of symptomatology: analysis from the international renal cell carcinoma-venous thrombus consortium (ircc-vtc).The Journal of Urology , Volume 193 , Issue 4 , e533. 2015

S

 

27*

Oderda, M; Gontero, P; Marra, G; Walz, J; Sanchez-Salas, R; Bastian, P; Van Der Poel, H; Chun, F; Graefen, M ; Tombal, B; Chlosta, P; Marchioro, G; Marco, B; Briganti, A; Tosco, L; Spahn, M; Karnes, Rj; Joniau, S Is Gleason Score Upgrading To 8-10 At Radical Prostatectomy A Predictor Of Biochemical Recurrence? A Retrospective Analysis Of 7310 High-Risk Cases From The Empact Database Anticancer Research, Vol 35 Issue: 6 Pages: 3676-3677 Meeting Abstract: 104, Published: Jun 2015

S

 

28*

Kaushik, D; Murphy, C; Briganti, A; Gontero, P; Spahn, M; Joniau, S; Karnes, Rj. Risk stratification among men undergoing radical prostatectomy for high-risk prostate cancer in us cohort: an empact study

Journal of urology.vol 191 issue: 4 pages: e473-e473 supplement: s published: apr 2014

S

 

29*

Linares, E; Martinez-Salamanca, JI; Novara, G; Bertini, R; Carballido, J; Chromecki, T; Ciancio, G; Daneshmand, S; Evans, C; Gontero, P; Gonzalez, J; Haferkamp, A; Hohenfellner, M; Huang, WC; Koppie, T; Lorentz, A; Ballesteros, CM; Master, V; Matloob, R; McKiernan, J; Mlynarczyk, C; Montorsi, F; Nguyen, H; Pahernik, S; Palou, J; Pruthi, R; Ramaswamy, K; Rodriguez-Faba, O; Russo, P; Spahn, M; Shariat, S; Terrone, C; Tilki, D; Vergho, D; Volpe, A; Wallen, E; Xylinas, E; Zigeuner, R; Libertino, JA. Cancer-specific survival and predictors in patients with ct3b kidney cancer: data of the ircvt rcc venous thrombus consortium. JOURNAL OF UROLOGYVol: 191 Issue: 4 Pages: . E646-E646 Supplement: S. APR 2014

S

 

30*

Faba, OR; Martnez, JI; Tilki, D; Dall'Era, MA; Nguyen, HG; Roberto, B; Carballido, JA; Chromecki, T; Ciancio, G; Daneshmand, S; Hu, B; Gontero, P; Gonzalez, J; Haferkamp, A; Hohenfellner, M; Huang, WC; Koppie, TM; Lorentz, A; Mandel, P; Master, VA; Matloob, R; McKiernan, JM; Mlynarczyk, CM; Montorsi, F; Novara, G; Pahernik, S; Pruthi, RS; Ramaswamy, K; Russo, P; Shariat, SF; Spahn, M; Terrone, C; Vergho, D; Wallen, EM; Xylinas, E; Zigeuner, R; Libertino, JA; Evans, CP; Palou, J. Impact of microscopic vein invasion on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Journal of urology Vol 191 Issue: 4 Pages: E318-E319 Supplement: S, April 2014

S

 

31*

Tosco L, van Poppel H, Van den Broeck T, Bastian P, Briganti A, Chun FK, Gontero P, Hsu CY, Karnes RJ, Marchioro G, Sanchez-Salas R, Spahn M, Tombal B, van der Poel H, Joniau S.

The effect of pathologic T-stage and Gleason score on cancer-specific survival in patients with positive surgical margins after surgery for high-risk prostate cancer.  Journal of Clinical Oncology  Volume: 32   Issue: 4   Supplement: S   Meeting Abstract: 140   Published: FEB 1 2014

S

 

32*

Gandaglia G, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun F, Sun F, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz P, Van Poppel H, Karnes J, Briganti A.

The impact of time to biochemical recurrence on cancer-specific mortality in patients with high-risk prostate cancer treated with radical prostatectomy: A competing-risks regression analysis. European Urology Supplements, Volume 13, Issue 1, April 2014, Pages e635-e635a

S

 

33*

Thalmann GN, Roth B, Spahn M, Zehnder P, Burkhard FC.

Outcome after treatment of small cell cancer of the bladder by neoadjuvant chemotherapy and radical cystectomy with extended pelvic lymph node dissection. European Urology Supplements, Volume 13, Issue 1, April 2014, Page e125

S

 

34*

Tosco L, Bastian P, Chun F, Gontero P, Hsu CY, Karnes J, Marchioro G, Sanchez-Salas R, Spahn M, Tombal B, Van Den Broeck T, Van Der Poel, H, Van Poppel H, Joniau S, European Multicenter Prostate Cancer Clinical and Translational research group (EMPaCT)

In high-risk prostate cancer, more than 3 positive nodes at radical prostatectomy represent an independent predictor of worse CSS, while 1 to 3 positive nodes do not influence CSS European Urology Supplements, Volume 13, Issue 1, April 2014, Pages e639-e639a

S

 

35*

Tosco L, Laenen A, Bastian P, Briganti A, Chun F, Gontero P, Hsu CY, Karnes J, Marchioro G, Sanchez-Salas R, Spahn M, Tombal B, Van Den Broeck T, Van Der Poel H, Van Poppel H, Joniau S, European Multicenter Prostate Cancer Clinical and Translational research group (EMPaCT)

In high-risk prostate cancer, prognostic factors predict cancer related death in a time-dependent fashion following surgery: A multi-institutional competing risk analysis European Urology Supplements, Volume 13, Issue 1, April 2014, Pages e634-e634a

S

 

36*

Tosco L, Laenen A, Bastian P, Briganti A, Chun F, Gontero P, Hsu CY, Karnes J, Marchioro G, Sanchez-Salas R, Spahn M, Tombal B, Van Den Broeck T, Van Der Poel H, Van Poppel H, Joniau S, European Multicenter Prostate Cancer Clinical and Translational research group (EMPaCT)

Combination of postoperative prognostic features to predict cancer specific survival in high-risk prostate cancer: A multi institutional competing risk analysis. European Urology Supplements, Volume 13, Issue 1, April 2014, Pages e638-e638a

S

 

37*

Linares E, Martínez-Salamanca J, Novara G, Bertini R, Carballido J, Chromecki T, Ciancio G, Daneshmand S, Evans, Davis C, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang W, Koppie T, Lorentz A, Martínez Ballesteros C, Master V, Matloob R, McKiernan J, Mlynarczyk C, Montorsi F, Nguyen H, Pahernik S, Palou J,Pruthi R, Ramaswamy C, Rodríguez-Faba O, Russo P, Spahn M, Shariat S, Terrone A, Tilki D, Vergho D, Volpe A, Wallen E, Xylinas E, Zigeuner R

Libertino J. Cancer-specific survival and predictors in patients with cT3b kidney cancer: Data of the CVT RCC Venous Thrombus Consortium

The Journal of Urology, Vol. 191, Issue 4, e646

S

 

38*

Nguyen H, Tilki D, Dall’Era M, Bertini R, Carballido J,

Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang W, Koppie T, Lorentz, A

Mandel P, Martinez-Salamanca J, Master V, Matloob R, McKiernan J, Mlynarczyk C, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi R, Ramaswamy C, Rodriguez Faba O, Russo P,

Shariat S, Spahn M, Terrone C, Vergho D, Wallen E, Xylinas E,

Zigeuner R, Libertino J,  Evans C. Does the use of cardiopulmonary by-pass (CPB) impact survival in patients undergoing nephrectomy/level iii-iv tumor thrombectomy? A multi-institutional analysis.The Journal of Urology, Vol. 191, Issue 4, e645–e646

S

 

39*

Joniau S, Tosco L, Briganti A, Gontero P, Bastian P, Chun F, Hsu CY, Marchioro G, Sanchez Salas R, Tombal B, Van Der Poel H, Karnes J, Spahn M. Changing trends in the clinical presentation of high risk prostate cancer over the last 22 years. The Journal of Urology, Vol. 191, Issue 4, e922

S

 

40*

Gontero P, Sylvester R, Pisano F, Joniau S, Van der Eeckt K, Serretta V, Larre S, Di Stasi S, van Rhjin B, Witjes A, Grotenhuis A, Kimeney B,

Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom P, Poitiers J, Malats N, Baniel N,  Mano R, Cai T,Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Palou J, Dalbagni G, Xylinas E,

Shariat S, Karnes J. The impact of re-tur on clinical outcomes in a large cohort of T1G3 patients treated with BCG. The Journal of Urology, Vol. 191, Issue 4, e569–e570

S

 

41*

Moltzahn F, Karnes J, Gontero P, Kneitz B, Tombal B, Bader P, Frohneberg D, van Poppel H, Joniau S, Spahn M. Predicting prostate cancer specific outcome after radical prostatectomy among men with cT3b/4 Pca with or without additional high risk factors: A multi-institutional outcome study of 266 patients. The Journal of Urology, Vol. 191, Issue 4, e460, 2014

S

 

42*

Gandaglia G, Abdollah F, Bianchi M, Sun M, Karakiewicz P, Shariat S, Joniau S, Spahn M, Gontero P, Marchioro G, Tombal B, Bastian P, Montorsi F, Van Der Poel H, Sanchez-SalasR, Briganti A.

Impact of time to biochemical recurrence on cancer-specific mortality in patients with high-risk prostate cancer treated with radical prostatectomy: a competing-risks regression Analysis The Journal of Urology, Vol. 191, Issue 4, e853

S

 

43*

Hakim L, Spahn M, Gontero P, Van Bruwaene S, Briganti A, Hsu C.Y, Jeffrey K, Joniau S. Cancer volume is an independent predictor for biochemical progression and clinical failure in high-risk prostate cancer patients following radical prostatectomy : A single centre experience. Eur Urol Suppl 2013;12;e468

S

 

44*

Van Den Broeck T, Tosco L, Bastian P, Briganti  A, Chun J, Gontero P, Hsu CY, Karnes J, Marchioro G, Sanchez-Salas R, Spahn M, Tombal B, Van Der Poel H, Joniau S. Revision of the definition of high-risk prostate cancer (PCa): cT2c remains an independent risk factor. Eur Urol Suppl 12 (2013) 123–180

S

 

45*

Gontero P, Sylvester R, Pisano F, Joniau S, Van Der Eeckt K, Serretta V, Larrè S, Di Stasi S, Van Rhijn B, Witjes A, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom P.U, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Dalbagni G, Shariat S, Karnes J, Palou J. Prognostic factors and risk groups in T1G3 patients initially treated with BCG: Results of a multicenter retrospective series in 1743 patients. Eur Urol Suppl 2013;12;e697

S

 

46*

Van Den Broeck T, Tosco L, Bastian P, Briganti A, Chun J, Gontero J, Hsu CY, Karnes J, Marchioro G, Sanchez-Salas R, Spahn M, Tombal B, Van Der Poel H, Joniau S. Defining the real high-risk prostate cancer patient: Sub-stratification into three prognostic groups. Eur Urol Suppl 12 (2013) 123–180

S

 

47*

Joniau S, Alberts AR, Moltzahn F, Briganti A, Karnes J, Gontero P, Weyne E, Hsu CY, Marchioro G, Tombal B, Chun J, Bastian P, Van Der Poel H, Sanchez-Salas R, Spahn M. Predicting prostate cancer specific outcome after radical prostatectomy among men with (very) high-risk, locally advanced PCa with or without additional high risk factors: A multi institutional retrospective cohort study of 1644 patients. Eur Urol Suppl 2013;12;e688

S

 

48*

Bianchi M, Karnes JR, Joniau S, Spahn M, Gontero P, Chun FK, Hansen J, Marchioro G, Abdollah F, Tombal B, Capitanio U, Bastian P, Van Der Poel H, Sanchez-Salas R, Briganti A. Association between time to biochemical recurrence and cancer specific and other cause mortality in men with high risk prostate cancer treated with radical prostatectomy without adjuvant treatments. A multiinstitutional analysis Eur Urol Suppl 2013;12;e686

S

 

49*

Hakim L, Spahn M, Gontero P, Van Bruwaene S, Briganti A, Hsu CY, Jeffrey K, Joniau S. Cancer volume is an independent predictor for biochemical progression and clinical failure in high-risk prostate cancer patients following radical prostatectomy : A single centre experience Eur Urol Suppl 2013;12;e468

S

 

50*

Hsu CY, Spahn M, Briganti A, Karnes J, Gontero P, Marchioro G, Tombal B, Chun J, Bastian P, Van Der Poel H, Sanchez-Salas R, Joniau S. Oncological outcome and prognostic factors for locally advanced prostate cancer treated with radical prostatectomy: An EMPaCT study Eur Urol Suppl 2013;12;e911

S

 

51*

Spahn M, Krebs M, Schubert M, Riedmiller H, Kneitz B. MiR-221 targets IRF2 and SOCS3 - two negative regulators of the JAK/STAT pathway - and inhibits their expression in prostate cancer. Eur Urol Suppl 2013;12;e936

S

 

52*

Karnes J, Briganti A, Gontero P, Spahn M, Joniau S. Risk stratification among men undergoing radical prostatectomy for high risk prostate cancer in a U.S. cohort: An EMPaCT validation study. Eur Urol Suppl 2013;12;e471

S

 

53*

Bianchi M, Karnes J, Joniau S, Spahn M, Gontero P, Chun F, Hansen J, Marchioro G, Abdollah F, Tombal B,  Capitanio U, Bastian P, Van der Poel H, Sanchez-Salas R, Montorsi F, van Poppel H, Briganti A. Association between time to biochemical recurrence and cancer specific and other cause mortality in men with high risk prostate cancer treated with radical prostatectomy without adjuvant treatments. A multi-institutional analysis. J Urol 2013, Vol. 189, Issue 4, Supplement, E319-320

S

 

54*

Gontero P, Zitella A, Kneitz B, Pacchioni D, Giona S, Peraldo F, BrigantiA, Joniau S, Karnes J, Spahn M. Prognostic role of microrna 221 in high risk prostate cancer. J urol 2013, Vol. 189, Issue 4, Supplement, E328-329

S

 

55*

Gontero P, Sylvester R, Pisano F, Joniau S, Van der Eeckt K, Serretta, V, Iarre S, di Stasi S, Van Rhjin B, WitjesA, Grotenhuis A, Colombo R,  Briganti A, Babjuk, M, Soukup V, Malmstrom P, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Palou J, Dalbagni G, Shariat S, Karnes J. Prognostic Factors And Risk Groups In T1g3 Patients Initially Treated With Bcg: Results of a Multicenter Retrospective Series In 2530 Patients. J urol 2013, Vol. 189, Issue 4, Supplement, E698

S

 

56*

Martinez-Salamanca J, Novara G, Bertini R, Carballido J, Chromecki T, Ciancio G, Daneshmand S, Evans C, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang W, Koppie T, Lorentz A, Martinez-Ballesteros C, Master V, Matloob R, McKiernan J, Mlynarczyk C, Montorsi F, Hao N, Pahernik S, Palou J, Pruthi R, Ramaswamy K, Rodriguez-Faba O, Russo P, Spahn M, Shariat S, Terrone C, Tilki D, Vergho D, Volpe A,Wallen E, Xylinas E, Zigeuner R, Libertino J. Level of thrombous according to mayo clinic classification is an independent predictor of perioperative complications and cancer-related outcome: data of the IRCVT RCC venous thrombus consortium. J urol 2013, Vol. 189, Issue 4, Supplement,  E782

S

 

57*

Spahn M, Krebs M, Schubert M, Riedmiller H, Kneitz B.

Micro-rna-221 expression induces stat1 phosphorylation and sensitizes prostate cancer cells for the anitproliferative effects of IFN-gamma.

J Urol 2013, Vol. 189, Issue 4, Supplement, E326

S

 

58*

Tilki D, Dall'Era M, Nguyen H, Bertini R, Carballido J, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang W, Koppie T, Lorentz A, Martinez-Salamanca J, Master V, Matloob R, McKiernan J, Mlynarczyk C, Montorsi F, Novara, G, Pahernik S, PalouJ, Pruthi R,  Ramaswamy K, Rodriguez Faba O, Russo P, Shariat S, Spahn M, Terrone C, Vergho D, WallenE, Xylinas E, Zigeuner R, Libertino J, Evans C. Impact of histologic subtype on tumor thrombus level and cancer-specific survival in patients with renal cell carcinoma and vena cava thrombus. J Urol 2013, Vol. 189, Issue 4, Supplement, E751-752

S

 

59

Spahn, M., Krebs, M., Schubert, M., Riedmiller, H., Kneitz, B., The biomarker miR-221 regulates STAT1 signaling in prostate cancer by targeting IRF2. European Urology Supplements 2012.11, E844-E844.

S

 

60

Spahn, M., Kalogirou, C., Scholz, C.J., Kneitz, S., Riedmiller, H., Kneitz, B., EmpaCt. Dysregulation of miR-205 is involved in progression of high risk prostate carcinoma, predicts recurrence-free survival and inhibits expression of target oncogenes HER2/neu and HER3. European Urology Supplements 2012.11, E846-U784.

S

 

61

Spahn, M., Joniau, S., Abdollah, F., Tutolo, M., Di Trapani, E., Gontero, P., Kneitz, B., Bader, P., Frohneberg, D., Van Poppel, H., Karnes, R.J., EmpaCt. Outcome of multimodality treatment of cT4 very high-risk prostate cancer with radical cystectomy as initial step: A multi-institutional outcome study of 62 patients. European Urology Supplements 2012. 11, E362-U819.

S

 

62

Spahn, M., Briganti, A., Capitanio, U., Gontero, P., Burkhard, B., Bader, P., Frohneberg, D., Joniau, S., EmpaCT. High risk prostate with pT3-tumor and positive surgical margin - relevance for clinical failure and prostate cancer mortality: Results of a prospective single institution series. European Urology Supplements 2012. 11, E357-E357.

S

 

63

Spahn, M., Abdollah, F., Joniau, S., Stroebel, P., Gontero, P., Schubert, M., Kneitz, B., Briganti, A., EmpaCT. Predicting prostate cancer specific mortality in high risk prostate cancer. A novel preoperative nomogram including the new biomarker micro-RNA 221. European Urology Supplements 2012.11, E361-E361.

S

 

64

Schubert, M., Kneitz, B., Kneitz, S., Scholz, C.J., Joniau, S., Van Poppel, H., Riedmiller, H., Spahn, M., EmpacT, 2012b. Let-7b is down-regulated in high risk prostate cancer and correlates with clinical failure. European Urology Supplements 2012. 11, E436-U954.

S

 

65

Kocot, A., Spahn, M., Vergho, D., Loeser, A., Riedmiller, H. Secondary intussuscepted ileal nipple valve in continent cutaneous urinary diversion: Surgical technique and long-term results. European Urology Supplements 2012. 11, E1076-U1245.

S

 

66

Joniau, S., Spahn, M., Briganti, A., Tombal, B., Marchioro, G., Walz, J., Hsu, C.Y., Frohneberg, D., Graefen, M., Tizzani, A., Van Poppel, H., Gontero, P. Stratification of high-risk prostate cancer into prognostic categories; a European multiinstitutional study. European Urology Supplements 2012. 11, E158-U562.

S

 

67

Joniau, S., Spahn, M., Briganti, A., Marchioro, G., Tombal, B., Walz, J., Hsu, C.Y., Frohneberg, D., Graefen, M., Tizzani, A., Van Poppel, H., Gontero, P., EmpaCT. Pretreatment tables for the prediction of pathological outcomes of patients with locally advanced prostate cancer. European Urology Supplements 2012. 11, E148-U547.

S

 

68

Briganti, A., Joniau, S., Gontero, P., Abdollah, F., Passoni, N.M., Tombal, B., Marchioro, G., Kneitz, B., Walz, J., Frohneberg, D., Bangma, C.H., Graefen, M., Tizzani, A., Frea, B., Karnes, R.J., Montorsi, F., Van Poppel, H., Spahn, M. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. European urology 2012. 61, 584-592.

S

 

69

Spahn, M., Krebs, M., Schubert, M., Riedmiller, H., Kneitz, B.  The biomarker mir-221 regulates stat1 signaling in prostate cancer by targeting irf2. J. Urol. 2012.187, E535-E536.

S

 

70

Spahn, M., Juergen, C., Stroebel, P., Lerut, E., van Poppel, H., Riedmiller, H., Joniau, S., Kneitz, B. Validation of the new biomarker micro-rna-221 to predict cancer related death in high-risk prostate carcinoma - results of a metaanalysis. J. Urol. 2012. 187, E899-E900.

S

 

71

Spahn, M., Gontero, P., Briganti, A., Kneitz, B., Bader, P., Hsu, C.Y., Montorsi, F., van Poppel, H., Frohneberg, D., Karnes, J., Joniau, S. Radical prostatectomy for very high risk t3b/4 prostate cancer - long term results of a multiinstitutional experience. J. Urol. 2012. 187, E452-E453.

S

 

72

Spahn, M., Briganti, A., Capitanio, U., Kneitz, B., Gontero, P., Karnes, J.R., Schubert, M., Montorsi, F., Scholz, C.J., Bader, P., van Poppel, H.  Joniau, S., d. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease. The Journal of urology 2012. 188, 84-90.

S

 

73

Spahn, M., Abdolah, F., Joniau, S., Stroebel, P., Gontero, P., Schubert, M., Kneitz, B., Briganti, A. Development of a novel preoperative nomogram including the biomarker micro-rna 221-predicting cancer specific mortality in high risk prostate cancer. J. Urol. 187, 2012. E455-E455.

S

 

74

Schubert, M., Spahn, M., Riedmiller, H., Kneitz, B. FUNCTIONAL analysis of the mirna family let-7 in prostate cancer cell lines. J. Urol. 2012. 187, E533-E534.

S

 

75

Kocot, A., Spahn, M., Vergho, D., Loeser, A., Riedmiller, H. Secondary intussuscepted ileal nipple valve in continent cutaneous urinary diversion: surgical technique and long-term results. J. Urol. 2012. 187, E472-E473.

S

 

76

Kocot, A., Spahn, M., Loeser, A., Riedmiller, H. Bilateral ileal ureteric replacement: indications, operative technique and long-term results. J. Urol. 2012. 187, E473-E473.

S

 

77

Joniau, S., Spahn, M., Chun, J., Bastian, P., Briganti, A., Tombal, B., Marchioro, G., Hsu, C.-Y., Frea, B., Montorsi, F., Van Poppel, H., van der Poel, H., Gontero, P. High-risk prostate cancer presenting with biopsy gleason score 8, 9 or 10: downgrading and cancer-specific survival. J. Urol. 2012. 187, E406-E406.

S

 

78

Joniau, S., Gontero, P., Briganti, A., Fieuws, S., Tombal, B., Marchioro, G., Hsu, C.-Y., Frea, B., Montorsi, F., Van Poppel, H., Spahn, M. Stratification of high-risk prostate cancer into prognostic categories; a european multi-institutional study. J. Urol. 2012. 187, E148-E149

S

 

79

Briganti, A., Joniau, S., Spahn, M., Karnes, J., Bianchi, M., Sun, M.I., Kneitz, B., Frohneberg, D., Bader, P., Marchioro, G., Terrone, C., Montorsi, F., Van Poppel, H., Gontero, P. The impact of age and comorbidities on survival after radical prostatectomy in high-risk prostate cancer patients: a competing-risks analysis. J. Urol. 2012. 187, E381-E381.

S

 

80

Briganti, A., Joniau, S., Spahn, M., Karnes, J., Bianchi, M., Sun, M., Kneitz, B., Frohneberg, D., Bader, P., Marchioro, G., Terrone, C., Montorsi, F., Van Poppel, H., Gontero, P. The impact of age and comorbidities on survival after radical prostatectomy in high-risk prostate cancer patients: a competing-risks analysis. J. Urol. 2012. 187, E381-E381.

S

 

81

Vergho, D.C., Kalogirou, C., Spahn, M., Loeser, A., Rosenwald, A., Riedmiller, H., Kneitz, B. MiR200c as outcome predictor of renal cell cancer patients with tumor thrombus of the inferior vena cava (IVC). European Urology Supplements  2012. 11, E314-E314.

S

 

82

Spahn, M., Krebs, M., Kneitz, S., Schubert, M., Riedmiller, H., Kneitz, B. MIR-221 over-expression in prostate carcinoma cells regulates the interferon-gamma signalling cascade. European Urology Supplements  2011.10, 202-203.

S

 

83

Spahn, M., Joniau, S., Kneitz, S., Scholz, C.J., Schubert, M., Kalogiru, C., Lerut, E., Stroebel, P., Van Poppel, H., Riedmiller, H., Kneitz, B. Downregulation of mir-221 is a strong and independent predictor of clinical progression and css in high-risk prostate cancer. European Urology Supplements 2011. 10, 238-239.

S

 

84

Spahn, M., Gontero, P., Briganti, A., Marchioro, G., Tombal, B., Walz, J., Hsu, C.Y., Bader, P., Frohneberg, D., Graefen, M., Tizzani, A., Van Cangh, P., Montorsi, F., Van Poppel, H., Joniau, S. Time to biochemical recurrence is a strong and independent predictor of css and os in high-risk prostate cancer. European Urology Supplements 2011.10, 217-217.

S

 

85

Spahn, M., Gontero, P., Briganti, A., Kneitz, B., Bader, P., Hsu, C.Y., Van Poppel, H., Frohneberg, D., Joniau, S., EmpaC. Radical prostatectomy for very high risk T3b/4 prostate cancer - results of a multiinstitutional experience. European Urology Supplements 2011. 11, 355

S

 

86

Loeser, A., Katzenberger, T., Kocot, A., Vergho, D.C., Spahn, M., Riedmiller, H. Significance of cancer involvement of the ureter and its meaning for upper urinary tract recurrence in patients undergoing radical cystectomy for bladder cancer. European Urology Supplements 2011. 10, 242-242.

S

 

87

Joniau, S., Van Baelen, A., Spahn, M., Briganti, A., Marchioro, G., Capitanio, U., Tombal, B., Hsu, C.Y., Akdogan, B., Bader, P., Frea, B., Frohneberg, D., Kneitz, B., Riedmiller, H., Tizzani, A., Van Poppel, H., Gontero, P. In high-risk prostate cancer, the number of lymph nodes removed at radical prostatectomy does not affect the risk of cancer related death or death from any cause. European Urology Supplements 2011. 10, 185-186.

S

 

88

Joniau, S., Van Baelen, A., Gontero, P., Briganti, A., Marchioro, G., Capitanio, U., Tombal, B., Hsu, C.Y., Akdogan, B., Bader, P., Frea, B., Frohneberg, D., Kneitz, B., Riedmiller, H., Tizzani, A., Van Poppel, H., Spahn, M. Three or more positive nodes at radical prostatectomy represent a significant cut-off value for css in high-risk prostate cancer, while 1 or 2 positive nodes do not influence CSS. European Urology Supplements 2011. 10, 323-323.

S

 

89

Joniau, S., Gontero, P., Spahn, M. The outcomes of radical prostatectomy monotherapy in high-risk prostate cancer. European Urology Supplements 2011. 10, 218-218.

S

 

90

Joniau, S., Gontero, P., Briganti, A., Marchioro, G., Capitanio, U., Tombal, B., Hsu, C.Y., Akdogan, B., Bader, P., Frea, B., Frohneberg, D., Kneitz, B., Riedmiller, H., Tizzani, A., Van Poppel, H., Spahn, M. The number of positive section margins in high-risk prostate cancer is a powerful and independent predictor of cancer-specific and overall survival in high-risk localized prostate cancer. European Urology Supplements 2011. 10, 285-285.

S

 

91

Briganti, A., Spahn, M., Joniau, S., Marchioro, G., Tombal, B., Hsu, H., Bader, P., Graefen, M., Tizzani, A., Van Cangh, P., Gontero, P., Van Poppel, H. Development and internal validation of nomograms predicting prostate cancer specific survival in patients with high risk disease. Results of a multi-institutional analysis. European Urology Supplements 2011. 10, 324-324.

S

 

92

Hsu, C.Y., Joniau, S., Spahn, M., Marchioro, G., Tombal, B., Gontero, P. Oncological outcomes and prognostic factors after radical prostatectomy in T3a prostate cancer: a multi-center experience. European Urology Supplements 2011. 10, 218-218.

S

 

93

Spahn, M., Kneitz, S., Krebs, M., Riedmiller, H. and Kneitz, B. Overexpression of the biomarker mir-221 regulated the interferon-gamma signalling cascade in prostate carcinoma cells. J Urol 2011, Vol. 185, Issue 4, Supplement, e511

S

 

94

Spahn, M., Reiß, C., Adam, P., Ströbel, P., Riedmiller, H. and Kneitz, B. Development of new mouse models for insignificant and lethal prostate cancer. J Urol 2011, Vol. 185, Issue 4, Supplement, e516

S

 

95

Spahn, M., Briganti, A., Capitanio, U., Gontero, P., Kneitz, B., Bader, P., Van Poppel, H., Frohneberg, D. and Joniau, S. pT3-prostate cancer-positive surgical margin at bladder neck is an independant predictor of local failure and prostate cancer mortality: results of a prospective single institution series. J Urol 2011, Vol. 185, Issue 4, Supplement, e591

S

 

96

Spahn, M., Gontero, P., Kneitz, B., Bader, P., Van Poppel, H., Frohneberg, D. and Joniau, S. Outcome of multimodality treatment of very high-risk T4-prostate cancer with radical cystectomy as initial step. . J Urol 2011, Vol. 185, Issue 4, Supplement, e719

S

 

97

Spahn, M., Joniau, S., Kneitz, S., Scholz, C-J., Kalogirou, C., Lerut, E., Ströbel, P., Schubert, M., Van Poppel, H., Riedmiller H. and Kneitz, B. Micro-rna-221 is a strong and independent predictor of clinical progression and css in high-risk prostate cancer. J Urol 2011, Vol. 185, Issue 4, Supplement, e653-e654

S

 

98

Joniau, S., Spahn, M., Briganti, A., Marchioro, M., Capitanio, U., Bader, P., Tombal, B., Frea, B., Tizzani, A., Riedmiller, H., Van Poppel, H., Gontero, P. RRP as stand-alone therapy for high-risk prostate cancer. J Urol 2011, Vol. 185, Issue 4, Supplement, e267

S

 

99

Gontero, P., Joniau, S., Spahn, M. and Giona S. In high-risk prostate cancer, age, but not charlson score is a major predictor of overall survival. J Urol 2011, Vol. 185, Issue 4, Supplement, e196

S

 

100

Joniau, S., Hsu, CY., Spahn, M., Marchioro, G., Briganti, A., Capitanio, U., Bader, P., Tombal, B., Frea, B., Tizzani, A., Riedmiller, H., Van Poppel, H. and Gontero, P. Oncological outcomes after radical prostatectomy in locally advanced prostate cancer: a multi-center experience. J Urol 2011, Vol. 185, Issue 4, Supplement, e190-e191

S

 

101

Joniau, S., Van Baelen, A., Gontero, P., Briganti, A., Marchioro, G., Capitanio, U., Bader, P., Tombal, B., Bury, K., Frea, B., Tizzani, A., Riedmiller, H., Van Poppel, H. and Spahn, M. In high-risk prostate cancer, 3 or more positive nodes at radical prostatectomy represent an independent predictor of worse css, while 1 or 2 positive nodes do not influence css. J Urol 2011, Vol. 185, Issue 4, Supplement, e119-e120

S

 

102

Briganti, A., Spahn, M., Joniau, S., Gontero, P., Marchioro, G., Tombal, B., Hsu, CY:, Bader, P.,  Graefen, M., Tizzani, A., Van Cangh, P., Montorsi, F. and Van Poppe, H. Development and internal validation of nomograms predicting prostate cancer specific survival in patients with high risk disease. Results of a multi-institutional analysis. J Urol 2011, Vol. 185, Issue 4, Supplement, e284

S

 

103

Joniau, S., Gontero, P., Briganti, A., Marchioro, G., Capitanio, U., Bader, P., Tombal, B., Frea, B.,  Tizzani, A., Riedmiller, H., Van Poppel, H. and Spahn, M. The number of positive section margins in high-risk prostate cancer is a powerful and independent predictor of cancer-specific and overall survival in high-risk localized. J Urol 2011, Vol. 185, Issue 4, Supplement, e191

S

 

104

Joniau,S., Van Baelen, A., Spahn, M., Briganti, A., Marchioro, G., Capitanio, U., Bader, P., Tombal, B., Bury, K., Frea, B., Tizzani, A., Riedmiller, H., Van Poppel, H. and Gontero, P. In high-risk prostate cancer, a pelvic lymph node dissection with >20 lymph nodes removed at radical prostatectomy significantly improves overall survival. J Urol 2011, Vol. 185, Issue 4, Supplement, e118-e119

S

 

105

Loeser, A., Katzenberger, T., Kocot, A., Vergho, D., Spahn, M. and Riedmiller, H. Significance of cancer involvement of the ureter and its meaning for upper urinary tract recurrence in patients undergoing radical cystectomy for bladder cancer. J Urol 2011, Vol. 185, Issue 4, Supplement, e461-e462

S

 

106

Gontero P, Oderda M, Marson F, Gillo A, Spahn M, Marchioro G, Tizzani A, Van Poppel H and Joniau S.: Is there a psa upper limit for radical prostatectomy? Anticancer research 30: 1375-1544 (2010)

S

 

107

Gontero P, Oderda M, Marson F, Gillo A, Spahn M, Briganti A, Marchioro G, Van Poppel H, Joniau S and  Tizzani A.: Is surgery for high-risk localized prostate cancer valid in the elderly population? An analysis of the influence of age and cancer-specific and overall survival. Anticancer research 30: 1375-1544 (2010)

S

 

108

Spahn M, Gontero P, Joniau S, Marchioro G, Fieuws S, Tombal B, Kneitz B, Hsu CY, Van Der Eeckt K, Bader P, Frohneberg D, Frea B, Terrone C, Tizzani A and Van Poppel H.: Predicting prostate cancer-specific outcome among men with psa ≥20 ng/ml and multiple unfavourable risk factors: a multi-institutional outcome study of 712 patients. Anticancer research.

30: 1375-1544 (2010)

S

 

109

Spahn M, Joniau S, Briganti A, Marchioro G, Tombal B, Walz J, Hsu CY, Bader P, Frohneberg D, Graefen M, Tizzani A, Van Cangh P, Montorsi F, Van Poppel H, Gontero P: Time to biochemical recurrence is a strong and independent predictor of css and os in high-risk prostate cancer. The Journal of Urology, Volume 183, Issue 4, Supplement 1, April 2010, Page e414

S

 

110

Spahn M, Gontero P, Kneitz B, Tombal B, Hsu CY, Van der Eeckt K, Marchioro G, Bader P, Frohneberg D, Tizzani A, Van Poppel H, Joniau S.: Predicting prostate cancer specific outcome after radical prostatectomy among men with psa &[ge] 20 ng/ml with or without additional high risk factors: a multi-institutional outcome study of 712 patients. The Journal of Urology, Volume 183, Issue 4, Supplement 1, April 2010, Page e227

S

 

111

Spahn M, Kneitz S, Scholz CJ, Kalogirou C, Ströbel P, Possner M, Riedmiller H, Kneitz B.: Micro rna-221 down-regulation promotes cancer cell proliferation, is related to the development of aggressive prostate cancer and predicts clinical recurrence. The Journal of Urology, Volume 183, Issue 4, Supplement 1, April 2010, Pages e213-e214

S

 

112

Gontero P, Spahn M, Briganti A, Marchioro G, Tombal B, Walz J, Bader P, Frohneberg D, Graefen M, Tizzani A, Van Cangh P, Montorsi F, Van Poppel H, Joniau S.

High-risk prostate cancer patients who have specimen-confined disease at pathology have exceptionally good outcomes after surgery.

The Journal of Urology, Volume 183, Issue 4, Supplement 1, April 2010, Page e788

S

 

113

Briganti A, Spahn M, Joniau S, Gontero P, Montorsi F, Marchioro G, Tombal B, Frohneberg D, Isbarn H, Bangma C, Schröder F, Kneitz B, Bader P, Graefen M, Tizzani A, Van Poppel H.: Predicting favourable pathological outcome in patients with clinical high risk prostate cancer. A novel nomogram based on a multi-institutional analysis. The Journal of Urology, Volume 183, Issue 4, Supplement 1, April 2010, Page e599

S

 

114

Vergho D, Kneitz S, Eckel N, Scherer C, Spahn M, Kneitz B, Riedmiller H.: Identification of mir-21 as tumor-suppressor and prognostic marker in renal cell cancer. The Journal of Urology, Volume 183, Issue 4, Supplement 1, April 2010, Pages e84-e85

S

 

115

Kneitz B, Reiß C, Adam P, Ströbel P, Riedmiller H, Spahn M.: Prostate specific deletion of the mismatch repair (mmr) gene mlh1 in mice cause neoplastic alterations of the prostate. The Journal of Urology, Volume 183, Issue 4, Supplement 1, April 2010, Page e214

S

 

116

Joniau S, Gontero P, Briganti A, Marchioro G, Tombal B, Walz J, Akdogan B, Hsu CY, Bader P, Frohneberg D, Graefen M, Kneitz B, Tizzani A, Van Cangh P, Montorsi F, Van Poppel H, Spahn M.: Value of elnd in lymph node negative patients with high-risk localized prostate cancer is uncertain. The Journal of Urology, Volume 183, Issue 4, Supplement 1, April 2010, Page e413

S

 

117

Spahn M, Gontero P, Kneitz B, Marchioro G, Bader P, Van Poppel H, Frohneberg D, Joniau S.: The role of positive section margins in patients with high risk prostate cancer treated by radical prostatectomy: prospective analysis of 566 patients. European Urology Supplements, Volume 9, Issue 2, April 2010, Page 224

S

 

118

Spahn M, Kneitz S, Scholz CJ, Kalogirou C, Ströbel P, Possner M, Riedmiller H, Kneitz B.: Downregulation of mir-221 promotes cancer cell proliferation, is related to the development of aggressive prostate cancer and predicts clinical recurrence. European Urology Supplements, Volume 9, Issue 2, April 2010, Pages 271-272

S

 

119

Spahn M, Gontero P, Kneitz B, Tombal B, Hsu CJ, Van Der Eeckt K, Marchioro G, Bader P, Frohneberg D, Tizzani A, Van Poppel H, Joniau S.: Predicting prostate cancer specific outcome among men with psa ≥ 20 ng/ml and multiple unfavourable risk factors: a multi-institutional outcome study of 712 patients. European Urology Supplements, Volume 9, Issue 2, April 2010, Page 267

S

 

120

Briganti A, Spahn M, Joniau S, Gontero P, Montorsi F, Marchioro G, Tombal B, Frohneberg D, Isbarn C, Bangma, C , Schroder F, Kneitz B, Bader P, Graefen M, Tizzani A, Van Poppel H.: Predicting favourable pathological outcome in patients with clinical high risk prostate cancer. A novel nomogram based on a multi-institutional analysis. European Urology Supplements, Volume 9, Issue 2, April 2010, Pages 317-318

S

 

121

Kocot A, Loeser A, Spahn M, Riedmiller H.: Ileal ureteric replacement with implantation into the native urinary bladder: long-term results. European Urology Supplements, Volume 9, Issue 2, April 2010, Page 151

S

 

122

Kneitz B, Reiß C, Adam P, Ströbel P, Riedmiller H, Spahn M.: Prostate specific deletion of the mismatch repair (mmr) gene mlh1 in mice cause neoplastic alterations of the prostate. European Urology Supplements, Volume 9, Issue 2, April 2010, Page 243

S

 

123

Gontero P, Kneitz S, Kneitz B, Tombal B, Walz J, Marchioro G, Bader P, Frohneberg D, Graefen M, Tizzani A, Van Poppel H, Joniau S, Spahn M.: The role of adjuvant hormonal treatment after surgery for high-risk localized prostate cancer-results of a multi-institutional matched analysis. European Urology Supplements, Volume 9, Issue 2, April 2010, Page 225

S

 

124

Joniau S, Gontero P, Briganti A, Tombal B, Marchioro G, Walz J, Vander Eeckt K, Hsu CY, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, Van Poppel H, Spahn M.: Cumulative number of high-risk factors is highly predictive of cancer-related outcomes and overall survival in patients with high-risk localized prostate cancer. European Urology Supplements, Volume 9, Issue 2, April 2010, Page 316

S

 

125

Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, Riedmiller H, Kneitz B.: Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Abstractband, EORTC-NCI-ASCO Annual Meeting on “Molecular Markers in Cancer”, 2009.

S

 

126

Spahn M, Gontero P, Joniau S, Tombal B, Bangma CH, Waz J, Eeckt KV, Bader P, Hsu CY, Marchioro G, Isbarn H, Frohneberg D, Graefen M, Schroder FH, Tizzani A, Van Cangh P, Van Poppel H: Outcome of multimodality treatment with radical prostatectomy as initial step for prostate cancer with psa > 20 ng/ml: A multi-institutional outcome study of 801 patients. Journal of Urology 2009;181:1279.

S

 

127

Spahn M, Joniau S, Gontero P, Tombal B, Walz J, Hsu CY, Marchioro G, Van Der Eeckt K, Bader P, Bangma C, Frohneberg D, Graefen M, Huland H, Schroder F, Tizzani A, Van Cangh P, Van Poppel H: The role of adjuvant treatment strategies after surgery for high-risk localized prostate cancer. European Urology Supplements 2009;8:251-251

S

 

128

Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, Riedmiller H, Kneitz B: Down-regulation of microrna-221 hallmarks prostate cancer metastasis and is a predictor of clinical recurrence. European Urology Supplements 2009;8:315-315.

S

 

129

Spahn M, Weiss C, Bader P, Frohneberg D, Studer UE, Burkhard FC: Is there a chance of cure for women with locally recurrent gynecological malignancy after exenterative surgery and urinary diversion? Journal of Urology 2009;181:809.

S

 

130

Kneitz B, Kneitz S, Stenger N, Strobel P, Riedmiller H, Spahn M: Comparison of mirna profiles in high and intermediate risk prostate carcinoma - role of mir-16 in development and progression of prostate carcinoma. European Urology Supplements 2009;8:316-316.

S

 

131

Spahn M, Kocot A, Löser A, Kneitz B, Riedmiller H.: Blasenhalsverschluß und kontinente Vesikostomie – ultima ratio bei komplexer Inkontinenz und/oder Obstruktion. Urologe A, Volume 48, Supplement 1 / September 2009

S

 

132

Spahn M, Joniau S, Gontero P, Kneitz B,  Bader P, Van Poppel H, Frohneberg D.: The role of positive section margins in patients with high risk prostate cancer treated by radical prostatectomy – Prospective analysis of 566 patients. Urologe A, Volume 48, Supplement 1 / September 2009

S

 

133

Spahn M, Joniau S, Tombal B, Bader P, Frohneberg D, Tizzani A, Van Cangh P, Van Poppel H, Gontero P.: Radical prostatectomy in very high risk localized prostate cancer (PSA >20 ng/ml + cT3/T4 + biopsy Gleason score ≥8). Urologe A, Volume 48, Supplement 1 / September 2009

S

 

134

Spahn M, Kneitz S, Stenger N, Scholz CJ, Rüdiger T, Ströbel P, Riedmiller H, Kneitz B: Down-regulation of microRNA-221 hallmarks prostate cancer metastasis and is a predictor of clinical recurrence. Urologe A, Volume 48, Supplement 1 / September 2009

S

 

135

Vergho D, Brix D, Löser A, Kocot A, Spahn M, Riedmiller H.: Tumornephrektomie bei Patienten mitNierenzellkarzinom und Thrombus der Vena cava inferior- outcome von 40 Patienten. Urologe A, Volume 48, Supplement 1 / September 2009

S

 

136

S. Joniau, P. Gontero, M. Spahn, D. Frohneberg, A. Tizzani, H. Van Poppel Radical Prostatectomy for Prostate Cancer with PSA >100 ng/ml
Urology, Volume 74, Issue 4, Supplement 1, October 2009, Pages S15-S16

S

 

137

Brix D, Fassnacht M, Fenske F, Quinkler M, Willenberg HS, Johanssen S, Spahn M, Gerharz EW, Riedmiller H, Allolio B, German Adrenocortical Canc G: Oncologic outcome of laparoscopic and open adrenalectomy in adrenocortical cancer: A case control study in 54 patients. European Urology Supplements 2009;8:305-305.

S

 

138

Brix D, Fassnacht M, Fenske W, Willenberg HS, Quinkler M, Johanssen S, Spahn M, Gerharz EW, Riedmiller H, Allolio B: Long-term outcome of laparoscopic versus open adrenalectomy for adrenocortical cancer. Journal of Urology 2009;181:26.

S

 

139

Gontero P, Joniau S, Spahn M, Tombal B, Eeckt KV, Bader P, Frohneberg D, Tizzani A, Van Cangh P, Van Poppel H: Radical prostatectomy in very high risk localized prostate cancer. Journal of Urology 2009;181:1062.

S

 

140

Gontero P, Spahn M, Joniau SG, Tombal B, Bangma C, Walz J, Hsu CY, Van Der Eeckt K, Marchioro G, Bader P, Frohneberg D, Graefen M, Huland H, Schroder F, Tizzani A, Van Cangh P, Van Poppel H: Outcome of multimodality treatment of clinically locally advanced prostate cancer with radical prostatectomy as initial step: A multi-institutional outcome study of 895 patients. European Urology Supplements 2009;8:251-251.

S

 

141

Joniau S, Gontero P, Spahn M, Tombal B, Walz J, Bangma C, Hsu CY, Marchioro G, Van Der Eeckt K, Bader P, Frohneberg D, Graefen M, Huland H, Schroder F, Tizzani A, Van Cangh P, Van Poppel H: The importance of positive section margins in patients with high risk prostate cancer treated with radical prostatectomy. European Urology Supplements 2009;8:274-274.

S

 

142

Joniau S, Spahn M, Gontero P, Tombal B, Bangma CH, Waz J, Hsu CY, Vander Eeckt K, Marchioro G, Bader P, Isbarn H, Frohneberg D, Graefen M, Schroder FH, Tizzani A, Van Cangh P, Van Poppel H: Outcome of multimodality treatment of high-risk localized prostate cancer (ct3-4 or psa >= 20 ng/ml or biopsy gleason score >= 8) with radical prostatectomy as initial step: A multi-institutional outcome study of 1413 patients. Journal of Urology 2009;181:1599.

S

 

143

Joniau SG, Spahn M, Gontero P, Tombal B, Bangma C, Walz J, Hsu CY, Van Der Eeckt K, Marchioro G, Bader P, Frohneberg D, Graefen M, Huland H, Schroder F, Tizzani A, Van Cangh P, Van Poppel H: Outcome of multimodality treatment of high-risk localized prostate cancer (ct3-4 or psa >= 20 ng/ml or biopsy gleason score >= 8) with radical prostatectomy as initial step: A multi-institutional outcome study of 1413 patients. European Urology Supplements 2009;8:252-252.

S

 

144

Kocot A, Spahn M, Gerharz EW, Lopau K, Riedmiller H: Renal transplantation into continent urinary reservoirs: Long-term follow up. European Urology Supplements 2009;8:145-145.

S

 

145

Kocot A, Spahn M, Lopau K, Gerharz EW, Riedmiller H: Renal transplantation and continent urinary diversion: Long-term follow-up. Journal of Urology 2009;181:2054.

S

 

146

Loeser A, Neumann M, Brix D, Kocot A, Vergho DC, Spahn M, Gerharz EW, Riedmiller H: Serum carcino-embryonic antigen (cea) and its possible use as tumour marker for secondary neoplasms in urinary intestinal reservoirs. Journal of Urology 2009;181:794.

S

 

147

Spahn M, Weiss C, Bader P, Kneitz B, Frohneberg D: Outcome of patients with high-risk prostate cancer following radical prostatectomy and stage dependent adjuvant androgen deprivation. European Urology Supplements 2008;7:120.

S

 

148

Spahn M, Kneitz S, Stenger N, Ströbel P, Kneitz B, Riedmiller H.: Identification of prostate cancer specific and outcome related microRNA expression profiles in prostate cancer. Urologe A, Volume 47, Supplement 1 / September 2008

S

 

149

Spahn M, Vergho D, Riedmiller H.: Perinealer Verschluß iatrogener rektourethraler Fisteln mit Mundschleimhautinterponat - Ergebnisse einer neuen Operationstechnik. Urologe A, Volume 47, Supplement 1 / September 2008

S

 

150

Kneitz B, Kneitz S, Eckel N, Rosenwald A, Spahn M, Hillig F, Riedmiller H.: Identification of tumor-suppressor and onco- microRNAs in renal cell cancer. Urologe A, Volume 47, Supplement 1 / September 2008

S

 

151

Spahn M, Weiss C, Bader P, Ströbel P, Kneitz B, Frohneberg D.: Long-term outcome of patients with high risk prostate cancer following radical prostectomy and stage dependent adjuvant androgen deprivation. Urologe A, Volume 47, Supplement 1 / September 2008

S

 

152

Kocot A, Spahn M, Ardelt P, Loeser A, Vergho D, Lopau K, Gerharz E, Riedmiller H.: Kontinente Harnableitung und Nierentransplantation: Langzeitergebnisse. Urologe A, Volume 47, Supplement 1 / September 2008

S

 

153

Hillig F, Kneitz S, Eckel N, Spahn M, Kneitz B, Riedmiller H: Identification of a mirna signature in renal cell cancer. Journal of Urology 2008;179:92-92.

S

 

154

Schwaab C, Westermann DH, Spahn M, Frohneberg D: Is endoscopic balloon dilatation of ureteral strictures an alternative to open surgery? Journal of Urology 2008;179:249-249

S

 

155

Spahn M, Bader P, Westermann D, Frohneberg D.: Das Zervixkarzinom-Rezidiv - eine Indikation zur Exenteration? Urologe A, Volume 46, Supplement 1 / September 2007

S

 

156

Bader P, Spahn M, Frohneberg D.Korreliert das Ausmaß der Lymphadenektomie mit dem Tumorverlauf des Lymphknoten-negativen Prostatakarzinoms (pN0) nach radikaler Prostatektomie? Urologe A, Volume 46, Supplement 1 / September 2007

S

 

157

Bader P, Spahn M, Woehr M, Frohneberg D: Extend of lymph node dissection in correlation to percentage of detected lymph node metastases and progression. European Urology Supplements 2007;6:89-89.

S

 

158

Bader P, Spahn M, Woehr M, Frohneberg D: Bladder cancer pt1g3 n0 m0 - results of early cystectomy. European Urology Supplements 2007;6:174-174.

S

 

159

Spahn M, Bader P, Woehr M, Frohneberg D: Pca with psa >20 - is there a chance of cure? European Urology Supplements 2006;5:212.

S

 

160

Spahn M, Bader P, Wöhr M, Frohneberg D.: Recurrent/advanced gynecological cancer - an indication for radical urological surgery? Urologe A, Volume 45, Supplement 4 / September 2006

S

 

161

Bader P, Spahn M, Wöhr M, Frohneberg D.: Das pT1G3 Blasenkarzinom – Ergebnisse der Frühzystektomie. Urologe A, Volume 45, Supplement 4 / September 2006

S

 

162

Wöhr M, Müller J, Spahn M, Bader P, Frohneberg D.: Transplantation - vom Mythos zum urologischen Routineeingriff. Urologe A, Volume 45, Supplement 4 / September 2006

S

 

163

Wöhr M, Spahn M, Bader P, Frohneberg D.: Differentialdiagnose des akuten Skrotums im Wandel der Zeit. Urologe A, Volume 45, Supplement 4 / September 2006

S

 

164

Bader P, Spahn M, Huber R, Frohneberg D: Prostate cancer with a low psa - a harmless tumour? European Urology Supplements 2005;4:8.

S

 

165

Bader P, Spahn M, Huber R, Frohneberg D: The incidental prostate cancer - is radical prostatectomy justified? Journal of Urology 2005;173:1008.

S

 

166

Bader P, Spahn M, Huber R, Echtle D, Frohneberg D: Limited lymph node dissection in prostate cancer may miss lymph node metastases and determines outcome of apparently pn0 prostate cancer. European Urology Supplements 2004;3:16.

S

 

167

Bader P, Spahn M, Huber R, Frohneberg D: The incidental prostate cancer: Watchful waiting or radical prostectomy? European Urology Supplements 2004;3:15.

S

 

168

Bader P, Spahn M, Huber RD, Echtle D, Frohneberg D: Bladder cancer pt1 g3 n0 m0: An often underestimated high risk tumour! European Urology Supplements 2003;2:86

S

 

169

Bader P, Mueller J, Spahn M, Echtle DR, Frohneberg D: Preoperative histologically understaging and it's impact on the decision for pelvic lymph node dissection in prostate cancer. Journal of Urology 2002;167:233-233.

S

 

170

Echtle DR, Mueller EM, Spahn M, Frohneberg DH: Prognostic significance of lymph node status and adjuvant chemotherapy. Journal of Urology 2002;167:284-284.

S

 

171

Subotic S, Martinez-Portillo FJ, Spahn M, Zendler S, Jünemann KP.: Alprostadil und Sildenafil unter audio-visueller Stimulation. Welches hat die größere Effektivität? Urologe A, Volume 40, Number 5 / August 2001

S

 

172

Braun PM, Spahn M, Michel MS, Scheepe JR, Alken P, Koehrmann KU: Modulith slk: First clinical application using ultrasound and the lithotrack system for flouroscopic localisation of urinary stones in eswl. European Urology 2000;37:15.

S

 

173

Braun PM, Weber A, Michel MS, Spahn M, Koehrmann KU, Krautschick A, Aiken P: Are auxilliary measures necessary in therapy of urolithiasis in children? Journal of Endourology 1998;12:S120.

S

 

Mitgliedschaften

Verbindung der Schweizer Ärzte FMH
Schweizerische Gesellschaft für Urologie
Deutsche Gesellschaft für Urologie DGU
European Association of Urology EAU
American Association of Urology AUA
Schweizer Arbeitsgemeinschaft Klinische Krebsforschung
European Organisation for Research and Treament of Cancer EORTC (seit 2014 Mitglied des SPECTA Leitungsgremium,
seit 2016 Mitglied des GU-Cancer board und des Quality Assurance Committee, Coordinator der Translationalen Forschungsplatform SPECTApros)
ÄrzteGesellschaft der Kantone Zürich und Aargau

Zentrum für Urologie Zürich

Telefon +41443872030

Zentrum für Urologie
Witellikerstrasse 40
CH-8032 Zürich
T +41 44 387 20 30
F +41 44 387 20 31

urologiezentrum.hirslanden@hirslanden.ch
www.hirslanden.ch